LG 101506

Drug Profile

LG 101506

Alternative Names: LG 100754; LG 101506 FA

Latest Information Update: 11 Aug 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Ligand Pharmaceuticals
  • Class Phenyl ethers; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Peroxisome proliferator-activated receptor modulators; Retinoid X receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 11 Aug 2006 No development reported - Preclinical for Obesity in USA (unspecified route)
  • 11 Aug 2006 No development reported - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 14 May 2003 Ligand and Eli Lilly have agreed to a second extention of their collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top